Description of Invention: ADP-ribosylation of arginine residues in proteins may be involved in cell adhesion and is crucial for the action of cholera toxin and E. coli heat-labile enterotoxin, agents involved in the pathogenesis of cholera and traveller's diarrhoea, respectively. ADP-ribosylation is reversed by ADP-ribosylarginine hydrolases, which cleave the ADP-ribose-arginine bond. ADP-ribosylarginine hydrolases from a variety of mammalian species and tissues were isolated, and the coding regions for the hydrolases were cloned and expressed. The availability of this new hydrolase cDNA and expression system provides a novel molecular approach for studying the role of ADP-ribosylation in cell function. The gene products may be useful in treating or preventing a variety of bacterial diseases, including cholera, that appear to be mediated via ADP-ribosylation.
Inventors: Joel Moss (NHLBI) Sally J Stanley (NHLBI) Maria S Nightingale (NHLBI) James J Murtagh (NHLBI) Lucia Monaco (NHLBI) Tatsuyuki Takada (NHLBI)
Patent Status: HHS, Reference No. E-076-1992/0
Research Tool -- Patent protection is not being pursued for this technology.
For Licensing Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4426 Fax: 301-402-0220